Protara Therapeutics, Inc. (TARA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-57.1%

$1.03

vs $2.41 price

Levered DCF

$1.08

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

2.7

Grey zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-3.98×	-2.43×	-0.53×	-0.46×	-1.61×	-5.15×	-4.52×	-9.14×
P/B	1.16×	0.65×	0.31×	0.3×	0.47×	0.88×	10.42×	11.37×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-3.19×	1.12×	0.32×	-0.19×	-1.04×	-0.23×	-7.74×	-10.34×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	14.58×	15.71×	11.17×	15.01×	21.66×	58.13×	11.96×	7.55×
Debt / equity	0.02×	0.03×	0.08×	0.06×	0.04×	0.01×	0×	0×
Interest coverage	0×	0×	0×	-58.98×	-27.34×	-1,013.06×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-29.2%	-26.7%	-59.2%	-64.6%	-29.2%	-17.1%	-234.5%	-124.4%
Return on invested capital	-32.3%	-28.6%	-59.1%	-61.8%	-28.1%	-17.2%	-214.9%	-127.6%
Return on assets	-27.4%	-24.6%	-51.2%	-58.2%	-27.4%	-16.7%	-214.9%	-108.1%
Free cash flow yield	-24.7%	-33.0%	-176.5%	-88.1%	-46.3%	-13.9%	-23.5%	-10.0%
Earnings yield	-25.2%	-41.0%	-189.7%	-218.6%	-62.3%	-19.4%	-22.5%	-10.9%
Enterprise value	$182M	-$49.6M	-$12.8M	$12.4M	$47.3M	$7.6M	$60.4M	$213.1M
Net debt / EBITDA	0.81×	3.58×	0.85×	0.27×	0.63×	4.96×	0.79×	0.94×
Cash conversion cycle (days)	-3,497	0	-2,605	0	0	-1,702	-16,334	-1,400